He has over two decades of rich experience in management consulting, advising and transforming leading generic pharmaceutical companies in India and global markets
Jubilant Pharmova Limited, an integrated global pharmaceutical company, has announced that Dr. Jaidev Rajpal will join the company as Head of its Generics business effective from October 11, 2022.
Dr. Rajpal is being appointed as Managing Director & CEO of Jubilant Pharmova's wholly owned subsidiary, Jubilant Generics Limited which is involved in the development, manufacturing and distribution of formulations to the US and Non-US markets and is also involved in the India branded pharmaceuticals business.
Jaidev has over two decades of rich experience in management consulting, advising and transforming leading generic pharmaceutical companies in India and global markets. He has a track record of delivering business transformation projects. He joins us from McKinsey & Company where he is working as a Partner in the pharmaceuticals and life sciences practice. Jaidev’s appointment will help the company in transforming its Generics business through commercial and operations excellence including portfolio and R&D rebalancing.
With this appointment, Jaidev will take over the Generics business from Pramod Yadav, who will continue to be the CEO of the Specialty Pharma (Radiopharma and Allergy Immunotherapy) and CDMO-Sterile Injectables businesses.
Commenting on the occasion, Shyam S. Bhartia, Chairman and Hari S. Bhartia, Co-Chairman and Managing Director, Jubilant Pharmova Limited said, “We are extremely pleased to have Jaidev with us in our endeavour to transform our Generics business to supplement performance of the overall Company. We are confident that with his rich experience and expertise in business transformation, Jaidev will add great value to our Generics business.”
On the occasion, Dr. Rajpal said, “I feel privileged to join Jubilant Generics which is committed to serving patients in India and across the world. Jubilant Generics is planning an exciting transformation journey to meet its objectives of providing highest quality medicines at the lowest cost. I look forward to working closely with the Jubilant team and driving holistic transformation to create value for all stakeholders.”
Subscribe To Our Newsletter & Stay Updated